<SUBMISSION>
<ACCESSION-NUMBER>0000950134-05-013421
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20050714
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20050715
<DATE-OF-FILING-DATE-CHANGE>20050715
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>SURMODICS INC
<CIK>0000924717
<ASSIGNED-SIC>6794
<IRS-NUMBER>411356149
<STATE-OF-INCORPORATION>MN
<FISCAL-YEAR-END>0930
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-23837
<FILM-NUMBER>05956563
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9924 W 74TH ST
<CITY>EDEN PRAIRIE
<STATE>MN
<ZIP>55344
<PHONE>6128292700
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9924 WEST 74TH ST
<CITY>EDEN PRAIRIE
<STATE>MN
<ZIP>55344
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BSI CORP
<DATE-CHANGED>19970506
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c96741e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>


<P align="center" style="font-size: 12pt"><B>Date of Report (Date of earliest event reported): July&nbsp;14, 2005</B>

<P align="center" style="font-size: 24pt"><B>SurModics, Inc.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of Registrant as Specified in its Charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="80%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">Minnesota<BR></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">(State or Other Jurisdiction of Incorporation)<BR></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD align="center" valign="top">0-23837
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">41-1356149</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">9924 West 74<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Street<BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">Eden Prairie, Minnesota 55344<BR></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">(Address of Principal Executive Offices and Zip Code)<BR></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">(952)&nbsp;829-2700<BR></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">(Registrant&#146;s telephone number, including area code)<BR></TD>
</TR>

<TR><TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">Not Applicable<BR></TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="center">(Former Name or Former Address, if Changed Since Last Report)<BR></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="90%" style="font-size: 10pt">
<TR>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="90%" style="font-size: 10pt">
<TR>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="90%" style="font-size: 10pt">
<TR>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="90%" style="font-size: 10pt">
<TR>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>
</TABLE>
</DIV>



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">







<!-- link2 "Item&nbsp;8.01 Other Events." -->

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;14, 2005, SurModics, Inc. issued a press release entitled &#147;SurModics Enters into
Agreement with University of Arizona to Develop Advanced Medical Therapies&#148;. The full text of the
press release is set forth in Exhibit&nbsp;99.1 attached hereto and is incorporated herein by reference.

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Financial Statements: None.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Pro forma financial information: None


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Exhibits:



<P align="left" style="margin-left:2%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release dated July&nbsp;14, 2005.

<!-- link1 "SIGNATURES" -->

<P align="center" style="font-size: 10pt">SIGNATURES



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SURMODICS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">By /s/ Philip D. Ankeny
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  July 15, 2005&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Philip D. Ankeny&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>


<P align="center" style="font-size: 10pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B>



<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX<BR>
to<BR>
FORM 8-K</B>



<P align="center" style="font-size: 10pt"><B>SURMODICS, INC.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Date of Report:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Commission File No.:</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>July&nbsp;14, 2005</B>
</TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="top"><B>0-23837</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>ITEM</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated July&nbsp;14, 2005.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c96741exv99w1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link2 "<U>Exhibit&nbsp;99.1</U>" -->

<P align="right" style="font-size: 10pt"><U><B>Exhibit&nbsp;99.1</B></U>



<P align="left" style="font-size: 10pt"><U><B>FOR IMMEDIATE RELEASE</B></U>



<P align="center" style="font-size: 14pt"><B>SurModics Enters into Agreement with University of Arizona to<BR>
Develop Advanced Medical Therapies</B>


<P align="left" style="font-size: 10pt">EDEN PRAIRIE, Minnesota &#151; July&nbsp;14, 2005 &#151; SurModics, Inc. (Nasdaq: SRDX), a leading provider
of surface modification and drug delivery technologies to the healthcare industry, announced today
that it has entered into a Collaborative Research agreement and license option with The University
of Arizona to develop advanced medical therapies. The joint development program is being conducted
in conjunction with Stuart Williams, Ph.D., a leader in the development of novel cardiovascular
implants using tissue engineering techniques. Dr.&nbsp;Williams has been a pioneer in understanding the
mechanisms and specific cell types involved in biomaterial healing and applying them to improve
device success.


<P align="left" style="font-size: 10pt">&#147;We are honored to enter into this agreement with the University of Arizona and work with Dr.
Williams, one of the leading researchers in the area of extracellular matrix (ECM)&nbsp;proteins and
biofunctional devices,&#148; said Bruce Barclay, President and CEO of SurModics. &#147;ECM proteins play a
critical role in promoting endothelial cell interactions. By incorporating these proteins onto
surfaces of devices, we believe the long term performance of implanted medical devices will improve
by accelerating the healing response. Dr.&nbsp;Williams&#146; work has already demonstrated the feasibility
of this approach, which we believe is applicable to many of our customers&#146; products and
technologies. This agreement is yet another example of our commitment to creating and offering
leading-edge proprietary technologies to our customers.&#148;


<P align="left" style="font-size: 10pt">&#147;This is an exciting partnership that will lead to improved function of current and future
generations of medical devices,&#148; stated Dr.&nbsp;Williams. &#147;I am very impressed with both the

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">technical ability of the scientific team at SurModics, and the company&#146;s proven track record of
success.&#148;


<P align="left" style="font-size: 10pt">Lise Duran, SurModics&#146; Vice President and General Manager of Regenerative Technologies commented,
&#147;We have made several exciting advancements in the past with Dr.&nbsp;Williams in surface modification
with ECM proteins and are thrilled to reestablish this relationship. We believe this joint program
will enable the development of innovative device therapies applicable over a broad range of device
products.&#148;


<P align="left" style="font-size: 10pt"><U><B>About SurModics, Inc.</B></U>


<P align="left" style="font-size: 10pt">SurModics, Inc. is a leading provider of surface modification technologies, in the areas of
biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical
diagnostics. SurModics partners with the world&#146;s foremost medical device, pharmaceutical and life
science companies to bring innovation together for better patient outcomes. A significant portion
of SurModics&#146; revenue is generated by royalties from the sale of commercial products resulting from
its corporate relationships. Recent collaborative efforts include the implementation of the
SurModics&#146; BRAVO drug delivery polymer matrix as a key component in the first-to-market
drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, MN and more information
about the company can be found at www.surmodics.com. The content of SurModics&#146; web site is not part
of this release or part of any filings the company makes with the SEC.


<P align="left" style="font-size: 10pt"><U><B>About The University of Arizona</B></U>


<P align="left" style="font-size: 10pt">As a public land-grant institution that opened its doors in 1891, the University of Arizona
provides an accessible environment for discovery where distinguished undergraduate, graduate, and
professional education are integrated with world-class basic and applied research and creative
achievement. The University of Arizona is among America&#146;s top research universities (based on NSF
total research expenditure data) and is one of about 60 select institutions recognized by
membership in the Association of American Universities. Serving 34,000 students, the University
includes the Tucson campus,

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">which is comprised of seven academic colleges, four professional colleges, and four colleges
comprising the Arizona Health Sciences Center (which also includes University Medical Center and
University Physicians). It also reaches people throughout the state by encompassing the Science and
Technology Park; the Cooperative Extension Service with locations throughout Arizona; the Phoenix
campus; and UA South, a branch campus in Sierra Vista.


<P align="left" style="font-size: 10pt"><U><B>About Professor Stuart Williams</B></U>


<P align="left" style="font-size: 10pt">Stuart Williams is Professor and Director, Division of Biomedical Engineering, Arizona Research
Laboratories. He is also a member of The University of Arizona&#146;s BIO5 Institute, a collaborative
bioresearch institute bringing together scientists from 5 disciplines &#151; agriculture, medicine,
pharmacy, basic science and engineering &#151; to solve complex biological problems. Dr.&nbsp;Williams is
Professor and Chairman, Biomedical Engineering Graduate Program, College of Graduate Studies at the
University of Arizona with secondary appointments in the Department of Physiology, Department of
Material Sciences and Engineering, and Department of Surgery.


<P align="left" style="font-size: 10pt">Stuart Williams is an inventor on numerous US and foreign patents and has authored over a hundred
refereed journal articles, abstracts and book chapters. His research interests focus on
cardiovascular biomedical engineering for coronary artery bypass grafts, ventricular assist and
total artificial heart and heart valves; identifying angiogenesis-specific gene expression in
angiogenic vessels using high density cDNA microarray expression screening; and developing new
technology to improve the success and lifespan of PTFE peripheral vascular grafts.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt"><U><B>Forward Looking Statements</B></U>


<P align="left" style="font-size: 10pt">Certain statements contained in this press release may be deemed to be forward-looking statements
under federal securities laws, and SurModics intends that such forward looking statements be
subject to the safe harbor created thereby. Factors that may cause actual results to differ from
the forward-looking statements include those described in the &#147;Risk Factors&#148; and other sections of
SurModics&#146; filings with the Securities and Exchange Commission. SurModics does not undertake an
obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.



<P align="left" style="font-size: 10pt"><U><B>Contact</B></U><BR>
Phil Ankeny, Chief Financial Officer and Vice President, Business Development<BR>
(952)&nbsp;829-2700



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
